Researchers are exploring various approaches to target KRAS mutations in cancer, including small molecular inhibitors and other therapies. These efforts aim to address the challenges of treating KRAS-mutant cancers, which have been considered difficult to treat. Several companies and studies are investigating potential treatments, with some reporting promising results, although the outcomes and effectiveness of these approaches are still being researched.